D. Boral Capital has initiated coverage of Cero Therapeutics, trading under the ticker (CERO, Financial), with a positive outlook, assigning a Buy rating and a price target of $11. The firm's analyst highlights Cero's unique position in the cell therapy market, attributing this to their innovative platform that enhances T cells with both innate and adaptive immune capabilities. This advancement has significant implications for treating solid tumors.
The firm suggests Cero Therapeutics is currently undervalued, considering its potential for innovation and upcoming pipeline developments expected in 2025. This perspective offers a promising proposition for long-term investors looking for opportunities in the early stages of biotechnology advancements. According to the analyst, the company's technology provides a compelling investment case within the rapidly evolving field of cell therapy.
